Stifel Initiates Coverage of Tectonic Therapeutic (TECX) with Buy Recommendation
Fintel reports that on April 14, 2026, Stifel initiated coverage of Tectonic Therapeutic (NasdaqGM:TECX) with a Buy recommendation.
Analyst Price Forecast Suggests 166.85% Upside
As of April 9, 2026, the average one-year price target for Tectonic Therapeutic is $79.82/share. The forecasts range from a low of $60.60 to a high of $106.05. The average price target represents an increase of 166.85% from its latest reported closing price of $29.91 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Tectonic Therapeutic is 0MM. The projected annual non-GAAP EPS is -4.54.
What is the Fund Sentiment?
There are 110 funds or institutions reporting positions in Tectonic Therapeutic. This is an decrease of 86 owner(s) or 43.88% in the last quarter. Average portfolio weight of all funds dedicated to TECX is 0.10%, an increase of 16.52%. Total shares owned by institutions increased in the last three months by 8.04% to 13,673K shares. 
The put/call ratio of TECX is 0.11, indicating a bullish outlook.
What are Other Shareholders Doing?
Standard Life Aberdeen holds 1,142K shares representing 6.08% ownership of the company. In its prior filing, the firm reported owning 356K shares , representing an increase of 68.81%. The firm increased its portfolio allocation in TECX by 132.56% over the last quarter.
Braidwell holds 928K shares representing 4.94% ownership of the company. In its prior filing, the firm reported owning 737K shares , representing an increase of 20.56%. The firm increased its portfolio allocation in TECX by 80.37% over the last quarter.
Baker Bros. Advisors holds 903K shares representing 4.81% ownership of the company. In its prior filing, the firm reported owning 100K shares , representing an increase of 88.93%. The firm increased its portfolio allocation in TECX by 873.23% over the last quarter.
5AM Venture Management holds 607K shares representing 3.23% ownership of the company. In its prior filing, the firm reported owning 512K shares , representing an increase of 15.66%. The firm increased its portfolio allocation in TECX by 35.31% over the last quarter.
Orbimed Advisors holds 575K shares representing 3.06% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.